Loading...
•
Sep 28, 2024
Hologic Q4 2024 Earnings Report
Hologic's Q4 2024 earnings were announced, with revenue of $987.9 million and GAAP diluted EPS of $0.76.
Key Takeaways
Hologic reported a strong fiscal fourth quarter in 2024, with a 4.5% increase in revenue to $987.9 million. GAAP diluted EPS was $0.76, and non-GAAP diluted EPS was $1.01. The company expects strong execution of its broad-based growth strategy in fiscal 2025.
Revenue increased by 4.5% to $987.9 million.
Diagnostics revenue increased 6.5%, driven by higher Molecular Diagnostics sales.
Breast Health revenue increased 6.4%, driven by strong Breast Imaging Service revenue and the addition of Endomagnetics.
The Company intends to enter into an accelerated share repurchase (ASR) agreement for $250 million of the Company’s common stock.
Revenue by Segment
Forward Guidance
Hologic provided financial guidance for the first quarter and full year 2025, incorporating the expected impact from the ongoing temporary stop-ship of Horizon DXA systems (Skeletal).
Positive Outlook
- Fiscal 2025 Revenue is expected to be $4,150 - $4,200
- Fiscal 2025 GAAP EPS is expected to be $3.53 - $3.63
- Fiscal 2025 Non-GAAP EPS is expected to be $4.25 - $4.35
- Q1 2025 Revenue is expected to be $1,025 - $1,035
- Q1 2025 Non-GAAP EPS is expected to be $1.00 - $1.03
Challenges Ahead
- Fiscal 2025 Revenue reported % increase (decrease) is expected to be 3.0% to 4.2%
- Fiscal 2025 Revenue Constant Currency % Increase (Decrease) is expected to be 2.3% to 3.5%
- Fiscal 2025 Revenue Organic % Increase (Decrease) is expected to be 1.7% to 3.0%
- Fiscal 2025 Revenue Organic excluding COVID-19 % Increase (Decrease) is expected to be 3.4% to 4.7%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...